IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-61153-x.html
   My bibliography  Save this article

Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial

Author

Listed:
  • Chong Ma

    (Moderna Inc)

  • Jiejun Du

    (Moderna Inc)

  • Lan Lan

    (Moderna Inc)

  • Archana Kapoor

    (Moderna Inc)

  • Gonzalo Perez Marc

    (Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich)

  • Gilberto Jimenez

    (Spotlight Research Center LLC)

  • Christopher J. A. Duncan

    (Newcastle University
    The Newcastle upon Tyne Hospitals NHS Foundation Trust)

  • Nancy Cam

    (Moderna Inc)

  • Nina Lin

    (Moderna Inc)

  • Frances Priddy

    (Moderna Inc)

  • Sanjay Garg

    (Moderna Inc)

  • Sonia K. Stoszek

    (Moderna Inc)

  • Christine A. Shaw

    (Moderna Inc)

  • Jaya Goswami

    (Moderna Inc)

  • Eleanor Wilson

    (Moderna Inc)

  • Rituparna Das

    (Moderna Inc)

  • Honghong Zhou

    (Moderna Inc)

  • Lingyi Zheng

    (Moderna Inc)

Abstract

Identifying an immunologic marker as a correlate of protection (CoP) for RSV vaccination is important. In the pivotal phase 3 trial, the mRNA-1345 vaccine demonstrated efficacy against RSV in older adults (NCT05127434). Here, we evaluate neutralizing antibodies (nAb) against RSV-A and -B, and IgG binding antibodies (bAb) to RSV fusion antigens as correlates of risk (CoR) and CoP against the pivotal trial’s efficacy endpoints of RSV lower respiratory tract disease with ≥2 or ≥3 signs/symptoms (RSV-LRTD-2+ and −3 + ) and acute respiratory disease (RSV-ARD). Day 29 RSV nAb and prefusion (preF) IgG demonstrate consistent inverse correlates with RSV endpoint occurrence. Day 29 point estimates (95% CIs) of the hazard ratio of each endpoint (RSV-LRTD-2 + , RSV-LRTD-3 + , RSV-ARD) per 10-fold increase in RSV-A nAb are 0.44 (0.30-0.65), 0.41 (0.20-0.84), and 0.45 (0.28-0.71), respectively, similar to RSV-B nAb and preF IgG. These results demonstrate Day 29 RSV nAb and preF IgG are CoRs and support their role as CoPs against RSV endpoints.

Suggested Citation

  • Chong Ma & Jiejun Du & Lan Lan & Archana Kapoor & Gonzalo Perez Marc & Gilberto Jimenez & Christopher J. A. Duncan & Nancy Cam & Nina Lin & Frances Priddy & Sanjay Garg & Sonia K. Stoszek & Christine , 2025. "Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial," Nature Communications, Nature, vol. 16(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-61153-x
    DOI: 10.1038/s41467-025-61153-x
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-61153-x
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-025-61153-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-61153-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.